Tag Archives: Platelet Rich Plasma Market

Platelet Rich Plasma Market is expected to rise US$451.9 mn with a CAGR of 12.50% up to 2024

As per the research study, the global market for PRP, which was valued at US$160.0 mn in 2015, is likely to expand at a CAGR of 12.50% during the period from 2016 to 2024 and report an opportunity worth US$451.9 mn by the end of the forecast period. The P-PRP segment, which occupied more than 60% of the overall market in 2015, is expected to remain leading throughout the forecast period.

View Report Overview: http://www.transparencymarketresearch.com/platelet-rich-plasma-market.html

Wide Presence of Leading Players to Ensure North America’s Dominance

The research report has also evaluated the global market for PRP on the basis of its geographical spread. It has identified North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America as the key regional markets for PRP across the world. Supported by the increasing count of orthopedic and cosmetic surgeries, North America led the global market with a majority share in 2015. Further, the wide presence of leading market players and the high awareness level among consumers about PRP therapy and devices are likely to ensure the leadership of this regional market throughout the forecast period.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4021

Asia Pacific is also expected to witness a healthy rise in the adoption of PRP therapies in the near future. The swiftly growing medical tourism industry, presence of well-established local players, increased base of the geriatric population, and the rising awareness regarding PRP among people are projected to boost the Asia Pacific PRP market over the forthcoming years, states the research report.

Increasing Count of Orthopedic Patients to Fuel Demand

“The significant increase in the count of orthopedic patients, worldwide, is the prime factor behind the tremendous progress of the global PRP market,” says a TMR analyst. As PRP therapy curtails the healing time of orthopedic or sports injuries from 4-6 months to 3-5 weeks with surgery, its demand for the treatment of orthopedic surgeries has increased remarkably and this is likely to remain so over the next few years.

The rise in cosmetic surgical procedures is another important factor that is likely to shape the future of the global PRP market. The high cost of PRP products and therapy is expected to hamper the growth of this market to some extent during the forecast period, notes the research study.

Buy Platelet Rich Plasma Market Research Report:

http://www.transparencymarketresearch.com/checkout.php?rep_id=4021&ltype=S

With a larger pool of players operating domestically and a smaller bunch of international participants, the global platelet-rich plasma (PRP) market demonstrates a semi-consolidated landscape. The top five players, namely, Harvest Technologies, Arthrex Inc., Zimmer Biomet, DePuy Synthes, and Stryker Corp. accounted for more than 80% of this market in 2015. Most of these are headquartered in North America. However, their focus is likely to shift towards emerging economies across Asia Pacific in the coming years, as this region is expected to offer lucrative opportunities on account of untapped potential.

Advertisements

Platelet Rich Plasma Market grows with increasing preference for PRP therapy in cases of sports injuries

The leading players in the Europe platelet rich plasma (PRP) market are EmCyte Corporation, Arthrex, Inc., AdiStem Ltd, Medira Ltd., and Biomet, Inc. Transparency Market Research observed that Anthex Inc. led the market in 2013 with its wide product portfolio that offers a variety of solutions for orthopedic disorders. “Companies must focus on developing impactful distribution and marketing strategies to target several small nations of Europe to retain their dominance in the near future,” states the lead author of this research report.

According to the research report, the Europe platelet rich plasma market is expected to be worth US$ 87.2 mn by 2022 from US$42.1 mn in 2013. During the forecast years of 2014 and 2022, the overall market is anticipated to rise at a CAGR of 8.30%. The key countries operating in the market are Greece, Spain, Italy, France, Germany, and the U.K. Analysts predict that the leukocyte-platelet rich fibrin (L-PRF) segment is expected to witness a significant growth rate in the coming years as it offers advantages such as reduced recovery period and cost-effectiveness.

This 89 page report gives readers a comprehensive overview of the Europe platelet rich plasma market. Browse through 8 data tables and 28 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/europe-platelet-rich-plasma-market.html

Market Thrives with Product Innovation

The market is also likely to be driven by the ongoing technological advancements in the production of platelet rich plasma. The advancements such as improved PRP preparation time has revolutionized the overall market. Product innovation is expected to result in a significant demand for platelet rich plasma in the near future across Europe. The growing advantages of using PRP products and devices is also likely to fuel the market growth during the forecast period. The innovation of PRP products and devices to treat male sexual disorders, vascular venous disorders, eye disorders, burn care, and lipofilling are expected to open up new avenues for growth for the Europe platelet rich plasma.

The high prevalence of chronic conditions is anticipated to be the primary growth driver for the Europe platelet rich plasma market in the near future. The high prevalence of chronic conditions related to orthopedics is expected to favor the growth of the global market. The increasing participation in sporting activities has led to a rise in orthopedic injuries in recent years, which has had a positive impact on the growth of the global market. The growing number of patients suffering from osteoporosis are also augmenting the demand for various types of platelet rich plasma products and devices as they are highly susceptible to fractures.

Controversy Stating PRP being Placebo Challenges Global Market

The aforementioned market drivers are being considerably challenged. The predominant hurdle for the Europe platelet rich plasma market is the exceptionally high cost of PRP products and devices. This issue is further complicated by the poor reimbursement policies. The market is also being stymied by the possibilities of failure of therapy being offered to patients and the chances of disease transfer. Additionally, the controversy surrounding PRP therapy technique has persistently inclined towards the theory that it is a mere placebo. All of these factors are expected to tug the market’s growth in the opposite direction.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Europe platelet rich plasma market during 2014 – 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4761

The review is based on Transparency Market Research’s report, titled “Platelet Rich Plasma Market – Europe Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 -2022.”

 

Platelet Rich Plasma Market: Emerging Trends and New Technologies Research 2016 – 2024

The top five players in the global platelet rich plasma (PRP) market contributed over 80% of the overall revenue generation in 2015, pointing towards the largely consolidated nature of the market. These players are Harvest Technologies Corporation, Arthrex Inc., Zimmer-Biomet, DePuy Synthes, Inc., and Stryker Corporation.

Among these, Harvest Technologies Corporation was the frontrunner, holding 25.2% of the overall market. Its dominance can be attributed to its strong presence in the cellular therapeutics and platelet-rich plasma segments, finds Transparency Market Research (TMR) in a study. “The majority of players have a strong focus towards research and development and product innovation to strengthen their foothold in the market,” says the author of the report.

This 176 page report gives readers a comprehensive overview of the platelet rich plasma market. Browse through 24 data tables and 66 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/platelet-rich-plasma-market.html

North America to Lead Revenue Generation through 2024

The global platelet rich plasma market was worth US$175.7 mn in 2016 and is poised to reach US$451.9 mn by 2024, progressing at a CAGR of 12.5% therein. On the basis of type, the pure-PRP segment will continue to dominate the market until 2024, accounting for 64.4% of the overall market value. Rich content of platelets and limited contamination with RBCs make this type the preferred choice of treatment. The pure-PRF segment is estimated to register a CAGR of 13.5% during the same period.

Geographically, North America will continue to be the leading revenue contributor until 2024, representing 48.3% of the overall market. The increasing prevalence of orthopedic diseases and growing geriatric population are contributing to the growth of the region. Asia Pacific is anticipated to post phenomenal growth, owing to the rising awareness regarding PRP treatments and booming medical tourism sector.

Growing Prevalence of Orthopedic Diseases Provides Fillip to Global Platelet Rich Plasma Market

The widening base of patients suffering from orthopedic disorders along with the increasing cases of sports injuries is one of the primary stimulants of the growth of the global platelet rich plasma market. The U.S. Centers for Disease Control and Prevention (CDC) estimates that the number of adults in the U.S. suffering from arthritis will reach 67 million by 2030 from 52.5 million in 2013. “PRP treatment reduces injury healing time from four to six months to three to five weeks with surgery. As a result, its preference will increase substantially over the coming years,” says a TMR analyst.

Rapid advancements in technologies are creating new application areas, such as hair restoration treatment, vampire facelift, and erectile dysfunction, of PRP. This, in turn, is working in favor of the global market. Moreover, the rising number of people undergoing cosmetic surgical procedures is augmenting the market.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving platelet rich plasma market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4021

Threat of Therapy Failure Limits Widespread Adoption

The threat of therapy failure is creating a major impediment to the growth of the global platelet rich plasma market. PRP has failed to show its efficacy in various therapeutic segments such as rotator cuff repair and total knee arthroplasty (TKA) surgery. In addition, the threat of chronic disease transfer such as hepatitis, syphilis, and other blood-borne diseases has induced skepticism regarding PRP treatment among end users. Moreover, the high costs of products and therapy combined with the shortage of reimbursement policies are negatively impacting the growth of the market.

The above data has been derived from a report by TMR, titled “Platelet Rich Plasma (PRP) Market (Type – Pure-Platelet Rich Plasma (P-PRP), Leukocyte-Platelet Rich Plasma (L-PRP), and Pure-Platelet-Rich Fibrin (P-PRF); Origin – Autologous, Homologous, and Allogeneic; Application – Orthopedic Surgery, Neurosurgery, Cosmetic Surgery, General Surgery, and Others (Urological Surgery, Cardiothoracic Surgery, and Periodontal Surgery)) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024.”

 

New Trends of Platelet Rich Plasma Market with Worldwide Industry Analysis to 2022

A study on the Europe platelet rich plasma (PRP) market has been recently published by Transparency Market Research (TMR). According to this report, the PRP market in Europe was valued at US$42.1 mn in 2013. Analysts project this market to rise at a CAGR of 8.30% during the period from 2014 to 2022 and reach US$87.2 mn by the end of the forecast period.The research report is titled “Platelet Rich Plasma Market – Europe Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 – 2022.”

Platelet-rich plasma (PRP) is the kind of blood plasma that contains a high number of platelets. As PRP is a concentrated source of autologous platelets, it contains a higher number of growth factors compared to normal blood concentration and other cytokines that activate healing of soft tissues and bones. It is widely utilized in the treatment of orthopedic disorders, neurological diseases, and various other injuries that require surgeries.

This 89 page report gives readers a comprehensive overview of the platelet rich plasma market. Browse through 8 data tables and 28 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/europe-platelet-rich-plasma-market.html

The rising prevalence of obesity and cardiovascular, neurological, and orthopedic disorders, the increasing cases of sports injuries, and the introduction of innovative and advanced devices for PRP preparation in Europe are bolstering the PRP market in this region. Additionally, the growing awareness among the European citizens regarding the PRP therapy and the benefits it offers is expected to support this market during the forecast period, notes the study.

In this report, the Europe PRP market has been studied on the basis of the region, PRP type, origin, and application. Regionally, the Europe market for PRP has been segmented into the U.K., Spain, France, Italy, Germany, and the Rest of Europe.

In 2013, the U.K. emerged as the leading domestic PRP market in Europe. The increase in orthopedic and reconstructive procedures, together with the rising number of bariatric surgeries, has boosted the U.K. PRP market significantly in the recent times. In addition to this, the increasing preference for PRP therapy in cases of sports injuries is likely to aid this market during the forecast period, states the research report.

Based on the type of PRP, the market has been classified into pure-platelet rich plasma (P-PRP), leukocyte-platelet rich fibrin (L-PRF), and leukocyte-platelet rich plasma (L-PRP). By origin, it has been segmented into allogenic, autologous, and homologous PRP. On the basis of application, the report has categorized the market into neurosurgery, cosmetic surgery, orthopedic surgery, general surgery, and various other surgeries such as cardiothoracic, oral, maxillofacial, urological, and periodontal surgeries.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving platelet rich plasma market during 2014 – 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4761

The study also presents an assessment of the competitive landscape prevalent in the Europe PRP market. Based on in-depth research it has been stated that the market is highly fragmented due to the presence of a number of small as well as large international participants. Arthrex Inc. led the overall market in 2013. The company’s strong emphasis on marketing and distribution strategies in various European nations such as Italy, the U.K., the Netherlands, Spain, France, Germany, and Denmark has helped it significantly to achieve this position.

Other key market participants mentioned in this study are Stryker Corp., Regen Lab S.A., Medira Ltd., Harvest Technologies Corp., Glofinn Oy, DePuy Synthes Inc., Biomet Inc., and AdiStem Ltd.

 

New Trends of Platelet Rich Plasma Market with Worldwide Industry Analysis to 2022

A study on the Europe platelets rich plasma (PRP) market has been recently published by Transparency Market Research (TMR). According to this report, the PRP market in Europe was valued at US$42.1 mn in 2013. Analysts project this market to rise at a CAGR of 8.30% during the period from 2014 to 2022 and reach US$87.2 mn by the end of the forecast period.The research report is titled “Platelet Rich Plasma Market – Europe Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 – 2022.”

Platelet-rich plasma (PRP) is the kind of blood plasma that contains a high number of platelets. As PRP is a concentrated source of autologous platelets, it contains a higher number of growth factors compared to normal blood concentration and other cytokines that activate healing of soft tissues and bones. It is widely utilized in the treatment of orthopedic disorders, neurological diseases, and various other injuries that require surgeries.

The rising prevalence of obesity and cardiovascular, neurological, and orthopedic disorders, the increasing cases of sports injuries, and the introduction of innovative and advanced devices for PRP preparation in Europe are bolstering the PRP market in this region. Additionally, the growing awareness among the European citizens regarding the PRP therapy and the benefits it offers is expected to support this market during the forecast period, notes the study.

In this report, the Europe PRP market has been studied on the basis of the region, PRP type, origin, and application. Regionally, the Europe market for PRP has been segmented into the U.K., Spain, France, Italy, Germany, and the Rest of Europe.

In 2013, the U.K. emerged as the leading domestic PRP market in Europe. The increase in orthopedic and reconstructive procedures, together with the rising number of bariatric surgeries, has boosted the U.K. PRP market significantly in the recent times. In addition to this, the increasing preference for PRP therapy in cases of sports injuries is likely to aid this market during the forecast period, states the research report.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4761

Based on the type of PRP, the market has been classified into pure-platelet rich plasma (P-PRP), leukocyte-platelet rich fibrin (L-PRF), and leukocyte-platelet rich plasma (L-PRP). By origin, it has been segmented into allogenic, autologous, and homologous PRP. On the basis of application, the report has categorized the market into neurosurgery, cosmetic surgery, orthopedic surgery, general surgery, and various other surgeries such as cardiothoracic, oral, maxillofacial, urological, and periodontal surgeries.

The study also presents an assessment of the competitive landscape prevalent in the Europe PRP market. Based on in-depth research it has been stated that the market is highly fragmented due to the presence of a number of small as well as large international participants. Arthrex Inc. led the overall market in 2013. The company’s strong emphasis on marketing and distribution strategies in various European nations such as Italy, the U.K., the Netherlands, Spain, France, Germany, and Denmark has helped it significantly to achieve this position.

Other key market participants mentioned in this study are Stryker Corp., Regen Lab S.A., Medira Ltd., Harvest Technologies Corp., Glofinn Oy, DePuy Synthes Inc., Biomet Inc., and AdiStem Ltd.